Granules India Ltd’s consolidated net profit increased 48 per cent to Rs 33 crore in the fourth quarter ended March 31, 2016 compared with Rs 22 crore in the corresponding quarter of the previous year.
Total revenues of the Hyderabad-based company grew 5 per cent to Rs 373 crore from Rs 355 crore in the year-ago period.
“We had a gentle top line growth but bottom line excelled with improved margins, validating our excellence in operational efficiency,’’ Krishna Prasad Chigurupati, Chairman & Managing Director, Granules India Ltd, said in a release.
For the full year 2015-16, consolidated net profit increased 30 per cent to Rs 118 crore (Rs 91 crore) on revenue of Rs 1,431 crore which marked 11 per cent increase over Rs 1,294 crore posted in the previous financial year.
The company’s board of directors has proposed a final dividend of 20 paise/share of face value of Rs 1 each.
During the year under review, Granules witnessed the commercialisation of its CRAMS business, ANDA approval for Ibuprofen Rx and the construction of a new capacity in addition to augmentation of R&D initiatives.
"This year and the year to come, we look forward to build a strong and agile company which will emerge as an efficient pharmaceutical manufacturing partner with a key focus on research and development,” Prasad said.